Barry E Greene
CIK 1291963 · President and CEO · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$15.71M
Companies
6
Total Filings
107
Lifetime Open-Market Net
-$58.92M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | Director | — | $26.00 | — | $0 | 1 | 2026-06-23 |
| KPTI | Director | 16,415 | $1.93 | $31.7K | $87.9K | 16 | 2026-05-26 |
| Sage Therapeutics, Inc. (SAGE) Delisted | President and CEO | 0 | $8.68 | $0 | $2.02M | 13 | 2025-07-31 |
| Acorda Therapeutics, Inc. (ACOR) Delisted | Director | 83 | $0.66 | $55 | -$290.2K | 20 | 2021-06-04 |
| ALNY | President | 68,588 | $228.61 | $15.68M | -$60.74M | 55 | 2020-09-11 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 51,254 | $8.16 | $418.2K | $0 | 2 | 2012-11-07 |
Recent Filings · Page 3 of 11
107 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-01-06 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-10-05 | Sage Therapeutics, Inc. (SAGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-09-11 | ALNY | Mixed | −155 | -$5.08M | EDGAR |
| 2020-08-11 | ALNY | Exer (M) | +4,931 | $349.9K | EDGAR |
| 2020-07-09 | ALNY | Mixed | — | -$3.36M | EDGAR |
| 2020-06-17 | Acorda Therapeutics, Inc. (ACOR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-26 | KPTI | Grant (A) | — | $0 | EDGAR |
| 2020-05-07 | ALNY | Mixed | — | -$3.14M | EDGAR |
| 2020-04-09 | ALNY | Mixed | +3,754 | -$174.3K | EDGAR |
| 2020-03-17 | KPTI | Exer (M) | +3,030 | $100 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.